A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
Investment fund Oaktree calls for board shakeup at Indivior, accusing company of 'value destruction'
With Indivior’s stock price in freefall over the past year, one of the company’s top investors is taking leadership to task, ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...
Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital ...
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting ...
On Tuesday night, millions of Americans watched as former president Donald J. Trump gathered up enough electoral votes needed ...
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...
AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback